1. Are we ready to close the discussion on the interchangeability of biosimilars?. Issue 10 (October 2019) Authors: Ebbers, Hans C.; Schellekens, Huub Journal: Drug discovery today Issue: Volume 24:Issue 10(2019) Page Start: 1963 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Contribution of animal studies to evaluate the similarity of biosimilars to reference products. Issue 4 (April 2015) Authors: van Meer, Peter J.K.; Ebbers, Hans C.; Kooijman, Marlous; Gispen-de Wied, Christine C.; Silva-Lima, Beatriz; Moors, Ellen H.M.; Schellekens, Huub Journal: Drug discovery today Issue: Volume 20:Issue 4(2015) Page Start: 483 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Development of a Transgenic Mouse Model to Study the Immunogenicity of Recombinant Human Insulin. Issue 5 (11th March 2014) Authors: Torosantucci, Riccardo; Brinks, Vera; Kijanka, Grzegorz; Halim, Liem Andhyk; Sauerborn, Melody; Schellekens, Huub; Jiskoot, Wim Journal: Journal of pharmaceutical sciences Issue: Volume 103:Issue 5(2014:May) Page Start: 1367 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. Development of ADA Against Recombinant Human Interferon Beta in Immune Tolerant Mice Requires Rapid Recruitment of CD4+ T Cells, Induces Formation of Germinal Centers but Lacks Susceptibility for (Most) Adjuvants. Issue 2 (12th September 2014) Authors: Kijanka, Grzegorz; Sauerborn, Melody; Boon, Louis; Schellekens, Huub; Brinks, Vera Journal: Journal of pharmaceutical sciences Issue: Volume 104:Issue 2(2015:Feb.) Page Start: 396 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. Impact of Biosimilar Insulins on Clinical Practice: Meeting Report. (January 2014) Authors: Dolinar, Richard O.; Edelman, Steve; Heinemann, Lutz; Home, Philip; Goyal, Shefali; Polonsky, William H.; Schellekens, Huub Journal: Journal of diabetes science and technology Issue: Volume 8:Number 1(2014:Jan.) Page Start: 179 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Iron nanomedicines induce Toll-like receptor activation, cytokine production and complement activation. (March 2017) Authors: Verhoef, Johan J.F.; de Groot, A. Marit; van Moorsel, Marc; Ritsema, Jeffrey; Beztsinna, Nataliia; Maas, Coen; Schellekens, Huub Journal: Biomaterials Issue: Volume 119(2017) Page Start: 68 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Safety and efficacy of biosimilars in oncology. Issue 11 (November 2016) Authors: Schellekens, Huub; Smolen, Josef S; Dicato, Mario; Rifkin, Robert M Journal: Lancet oncology Issue: Volume 17:Issue 11(2016:Nov.) Page Start: e502 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. Value for money of drug regulation. (June 2012) Authors: Bouvy, Jacoline C; Koopmanschap, Marc A; Schellekens, Huub Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 12:Number 3(2012) Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. Value for money of drug regulation. (June 2012) Authors: Bouvy, Jacoline C; Koopmanschap, Marc A; Schellekens, Huub Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 12:Number 3(2012) Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. Value for money of drug regulation. (June 2012) Authors: Bouvy, Jacoline C; Koopmanschap, Marc A; Schellekens, Huub Journal: Expert review of pharmacoeconomics & outcomes research Issue: Volume 12:Number 3(2012) Page Start: 247 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗